Alzheimer’s Association International Conference (AAIC) 2026 | iPharmaCenter

Leqembi Real-World LEADER Study validates the Real-World Performance

New interim findings from the LEADER study, a three-year retrospective analysis of Leqembi (lecanemab), indicate sustained therapeutic efficacy in a real-world clinical setting.

Analyzing data from 432 patients across 13 U.S. clinical sites, the study reports that 82.5% of individuals with early-stage Alzheimer’s disease (AD) experienced disease stabilization or cognitive improvement after an average treatment duration of 17 months.

Breakdown of the clinical outcomes reveals that 75.9% of the cohort maintained their baseline disease stage, while 6.6% demonstrated improvement, transitioning from mild AD dementia to mild cognitive impairment (MCI). Longitudinal adherence remains high, with 87% of patients continuing Leqembi therapy.

Data from the maintenance phase proved equally robust, as 80.7% of patients receiving intravenous maintenance and 85.7% of those receiving the subcutaneous formulation showed stabilization or improvement.

The LEADER study results emphasize a shifting paradigm in how Alzheimer’s care is delivered, highlighting a decisive migration of patient volume toward independent specialty infusion centers. These agile, specialized facilities are effectively overcoming operational hurdles, such as diagnostic screening, infusion scheduling, and mandatory serial MRI monitoring, that have historically hindered larger, bureaucratic hospital systems.

The data suggests that the "winning" care model is defined by multidisciplinary integration. Clinics that successfully synthesize neurology, radiology, and infusion services into a cohesive, patient-centric workflow are capturing greater market share. Conversely, traditional hospital systems hindered by internal silos are experiencing significant patient attrition. As clinical evidence of Leqembi’s real-world efficacy grows, stakeholders are increasingly prioritizing operational efficiency, signaling that future success for disease-modifying therapies will be as dependent on infrastructure and care-delivery models as it is on the pharmacological agents themselves.

Industry Context

For pharmaceutical manufacturers and providers, the LEADER study establishes a high standard for long-term therapeutic monitoring. The consistency of clinical outcomes across diverse patient populations, regardless of sex, race, ethnicity, or APOE genotype, provides strong empirical support for continued, long-term coverage by insurance payers.

Moving forward, the industry is expected to move toward the formal standardization of decentralized infusion networks. While the clinical efficacy of Leqembi is now bolstered by substantial real-world performance data, the next critical phase for the sector involves lowering the diagnostic and administrative burdens associated with therapy administration.

By demonstrating that continuous treatment can halt or delay the progression of Alzheimer’s, Eisai and Biogen have provided a compelling rationale for the sustained expansion of specialized, outpatient-based care networks.